LOS ANGELES, Jan. 7, 2021 /PRNewswire/ -- ImaginAb Inc., a
leading global provider of immuno-oncology imaging agents, today
announced it has signed a new multi-year, non-exclusive license
with Pfizer Inc. (NYSE: PFE) to supply 89Zr CD8 Immuno-PET agent,
which can be used to image CD8 T cells in cancer patients.
Quantitative imaging of CD8 T cells enables quicker
identification of drug efficacy, therefore potentially reducing the
length of clinical trials, reducing costs and helping new therapies
to advance to market faster, which ultimately will improve
treatment and care of cancer patients.
Under the terms of the agreement, ImaginAb will supply clinical
doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select
oncology clinical trials. In addition, ImaginAb will provide
technical, clinical, and regulatory support to
Pfizer. ImaginAb will receive license fees and payments for
manufacturing and other support. No other terms were disclosed.
This agreement expands upon the relationship between the
companies following the pre-competitive alliance between
ImaginAb, Pfizer and other global pharmaceutical companies which
focused on the development of 89Zr CD8 ImmunoPET technology. The
alliance, announced on October 14,
2019, has assisted in advancing the 89Zr CD8 Immuno-PET
technology.
Commenting on the announcement, Ian
Wilson, Chief Executive Officer of ImaginAb said: "Pfizer
continues to be a great partner and supporter of our efforts to
develop this innovative PET imaging technology, and we are
delighted to expand our relationship further.
Wilson continued "Imaginab is actively investing in the clinical
and global supply chain development of 89Zr CD8 Immuno-PET agent to
provide simple turnkey access to this novel technology. Our goal is
to enable the widespread use and adoption of 89Zr CD8 Immuno-PET
technology, which will help our partners to predict therapeutic
efficacy and treatment outcomes in cancer patients more precisely
and earlier in a clinical trial. Working with leading
pharmaceutical companies such as Pfizer, will help us achieve our
goal."
"CD8 T cells play such a pivotal role in immunotherapy of many
cancers and our 89Zr CD8 Immuno-PET is one of the most widely
used imaging technology used by pharmaceutical and biotech
companies to track CD8 T cells in patients."
For further information please contact:
ImaginAb
Ian Wilson
Email: info@imaginab.com
Phone: +1 310 645 1211
About ImaginAb
ImaginAb Inc. is biotechnology company focused on developing
radiopharmaceutical imaging and therapy agents. ImaginAb engineers
antibody fragments called minibodies that maintain the exquisite
specificity of full-length antibodies while remaining biologically
inert in the body. Used with widely available PET scan technology,
these novel minibodies illuminate high-value molecular targets,
providing physicians with a whole-body picture of immune
activity. ImaginAb is advancing a pipeline of minibodies
against oncology and immunology targets including the 89Zr CD8
ImmunoPET targeting CD8 T cells. ImaginAb's products have the
potential to improve patient care and lower healthcare costs. The
Company is backed by top tier venture capital firms and strategic
corporate firms including, Adage Capital, The Cycad Group, Norgine
ventures Jim Pallotta of the Raptor
Group, The Parker Institute for Cancer Immunotherapy, and Merck
(MSD) Pharma.
For more information about ImaginAb's pipeline and technology,
visit www.imaginab.com.
About CD8 ImmunoPET
The 89Zr CD8 Immuno-PET agent ([89Zr]-Df-IAB22M2C) is a
[89Zr]-labeled minibody that binds the CD8 receptor on human T
cells and is used for quantitative, non-invasive PET imaging of CD8
T cells in patients. CD8 T cells are the main effector cells
involved in the immune response against tumor cells induced by
immunotherapies and they also play a key role in multiple
autoimmune diseases. As such, quantitative imaging of CD8 T cells
can be used to diagnose the immune status of a patient, to measure
the efficacy of immunotherapies and predict patient outcomes.
Logo -
https://mma.prnewswire.com/media/221237/imaginab_inc___logo.jpg